112 related articles for article (PubMed ID: 10383042)
1. Decrease in serum pentosidine levels of ESRD patients during polysulfone haemodialysis.
Stein G; Franke S; Sperschneider H; Vienken J; Ueda Y; Miyata T; Kurokawa K
Nephrol Dial Transplant; 1999 Jun; 14(6):1606-8. PubMed ID: 10383042
[No Abstract] [Full Text] [Related]
2. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.
Stein G; Franke S; Mahiout A; Schneider S; Sperschneider H; Borst S; Vienken J
Nephrol Dial Transplant; 2001 May; 16(5):999-1008. PubMed ID: 11328907
[TBL] [Abstract][Full Text] [Related]
3. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
[TBL] [Abstract][Full Text] [Related]
4. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.
Suliman ME; Heimbürger O; Bárány P; Anderstam B; Pecoits-Filho R; Rodríguez Ayala E; Qureshi AR; Fehrman-Ekholm I; Lindholm B; Stenvinkel P
J Am Soc Nephrol; 2003 Jun; 14(6):1614-22. PubMed ID: 12761263
[TBL] [Abstract][Full Text] [Related]
5. [The effect of hemodialysis with frequent use of cuprophan and polysulfone membranes on activation of complement in patients with chronic renal failure].
Zukowska-Szczechowska E; Moczulski D; Grzeszczak W; Gosek K; Augustyn M; Staszewicz P
Pol Arch Med Wewn; 1996 Nov; 96(5):458-68. PubMed ID: 9091856
[TBL] [Abstract][Full Text] [Related]
6. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels.
Tessitore N; Lapolla A; Aricò NC; Poli A; Gammaro L; Bassi A; Bedogna V; Corgnati A; Reitano R; Fedele D; Lupo A
J Nephrol; 2004; 17(5):707-14. PubMed ID: 15593039
[TBL] [Abstract][Full Text] [Related]
7. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients.
Nascimento MM; Suliman ME; Bruchfeld A; Hayashi SY; Manfro RC; Qureshi AR; Pecoits-Filho R; Pachaly MA; Renner L; Stenvinkel P; Riella MC; Lindholm B
Nephrol Dial Transplant; 2004 Dec; 19(12):3112-6. PubMed ID: 15466879
[TBL] [Abstract][Full Text] [Related]
8. Hemodialysis techniques and advanced glycation end products.
Tessitore N; Lapolla A; Aricó CN; Gammaro L; Bernich P; Fedele D
Contrib Nephrol; 2001; (131):33-9. PubMed ID: 11125561
[No Abstract] [Full Text] [Related]
9. Ultrapure dialysate decreases plasma pentosidine, a marker of "carbonyl stress".
Izuhara Y; Miyata T; Saito K; Ishikawa N; Kakuta T; Nangaku M; Yoshida H; Saito A; Kurokawa K; van Ypersele de Strihou C
Am J Kidney Dis; 2004 Jun; 43(6):1024-9. PubMed ID: 15168382
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
Morimoto H; Nakao K; Fukuoka K; Sarai A; Yano A; Kihara T; Fukuda S; Wada J; Makino H
Nephrol Dial Transplant; 2005 Dec; 20(12):2775-82. PubMed ID: 16221689
[TBL] [Abstract][Full Text] [Related]
11. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients.
Furuya R; Kumagai H; Takahashi M; Sano K; Hishida A
Blood Purif; 2005; 23(4):311-6. PubMed ID: 15980621
[TBL] [Abstract][Full Text] [Related]
12. Quantification of the cross-link pentosidine in serum from normal and uremic subjects.
Takahashi M; Kushida K; Kawana K; Ishihara C; Denda M; Inoue T; Horiuchi K
Clin Chem; 1993 Oct; 39(10):2162-5. PubMed ID: 8403403
[TBL] [Abstract][Full Text] [Related]
13. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
[TBL] [Abstract][Full Text] [Related]
14. The effect of dialysis membrane type on plasma concentrations of pentosidine, a marker of carbonyl stress, in hemodialyzed patients.
Słowik-Zyłka D; Safranow K; Dziedziejko V; Ciechanowski K; Dziewanowski K; Chlubek D
Pol Arch Med Wewn; 2009 Oct; 119(10):614-20. PubMed ID: 19847136
[TBL] [Abstract][Full Text] [Related]
15. Association of serum pentosidine with arterial stiffness in hemodialysis patients.
Zhou Y; Yu Z; Jia H; Sun F; Ma L; Guo R; Peng L; Cui T
Artif Organs; 2010 Mar; 34(3):193-9. PubMed ID: 20447043
[TBL] [Abstract][Full Text] [Related]
16. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
[TBL] [Abstract][Full Text] [Related]
17. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.
Sanaka T; Funaki T; Tanaka T; Hoshi S; Niwayama J; Taitoh T; Nishimura H; Higuchi C
Nephron; 2002 May; 91(1):64-73. PubMed ID: 12021521
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis.
Fagugli RM; Vanholder R; De Smet R; Selvi A; Antolini F; Lameire N; Floridi A; Buoncristiani U
Int J Artif Organs; 2001 May; 24(5):256-62. PubMed ID: 11420874
[TBL] [Abstract][Full Text] [Related]
19. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis.
Kitauchi T; Yoshida K; Yoneda T; Saka T; Yoshikawa M; Ozono S; Hirao Y
Clin Exp Nephrol; 2004 Mar; 8(1):48-53. PubMed ID: 15067516
[TBL] [Abstract][Full Text] [Related]
20. The relationship between pentosidine and hemodialysis-related connective tissue disorders.
Sakata S; Takahashi M; Kushida K; Oikawa M; Hoshino H; Denda M; Inoue T
Nephron; 1998; 78(3):260-5. PubMed ID: 9546683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
